X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs DR. REDDYS LAB - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES DR. REDDYS LAB DIVIS LABORATORIES/
DR. REDDYS LAB
 
P/E (TTM) x 38.4 31.5 121.7% View Chart
P/BV x 6.2 3.4 184.1% View Chart
Dividend Yield % 0.7 0.8 92.5%  

Financials

 DIVIS LABORATORIES   DR. REDDYS LAB
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
DR. REDDYS LAB
Mar-18
DIVIS LABORATORIES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,1422,788 41.0%   
Low Rs5331,902 28.0%   
Sales per share (Unadj.) Rs146.6860.8 17.0%  
Earnings per share (Unadj.) Rs33.057.1 57.9%  
Cash flow per share (Unadj.) Rs38.4122.0 31.5%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.20.9 140.0%  
Book value per share (Unadj.) Rs222.8757.7 29.4%  
Shares outstanding (eoy) m265.47165.91 160.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.72.7 209.7%   
Avg P/E ratio x25.341.1 61.7%  
P/CF ratio (eoy) x21.819.2 113.5%  
Price / Book Value ratio x3.83.1 121.4%  
Dividend payout %30.335.0 86.4%   
Avg Mkt Cap Rs m222,318389,034 57.1%   
No. of employees `00010.823.5 45.7%   
Total wages/salary Rs m4,56132,149 14.2%   
Avg. sales/employee Rs Th3,616.06,070.8 59.6%   
Avg. wages/employee Rs Th423.81,366.6 31.0%   
Avg. net profit/employee Rs Th814.9402.5 202.5%   
INCOME DATA
Net Sales Rs m38,915142,810 27.2%  
Other income Rs m1,1341,552 73.1%   
Total revenues Rs m40,049144,362 27.7%   
Gross profit Rs m12,61723,512 53.7%  
Depreciation Rs m1,42510,772 13.2%   
Interest Rs m13788 1.7%   
Profit before tax Rs m12,31313,504 91.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,5434,380 80.9%   
Profit after tax Rs m8,7709,468 92.6%  
Gross profit margin %32.416.5 196.9%  
Effective tax rate %28.832.4 88.7%   
Net profit margin %22.56.6 339.9%  
BALANCE SHEET DATA
Current assets Rs m45,351104,984 43.2%   
Current liabilities Rs m6,50768,938 9.4%   
Net working cap to sales %99.825.2 395.5%  
Current ratio x7.01.5 457.6%  
Inventory Days Days12774 170.4%  
Debtors Days Days95104 91.9%  
Net fixed assets Rs m21,160104,385 20.3%   
Share capital Rs m531830 64.0%   
"Free" reserves Rs m58,625124,886 46.9%   
Net worth Rs m59,156125,716 47.1%   
Long term debt Rs m025,089 0.0%   
Total assets Rs m67,832225,443 30.1%  
Interest coverage x926.818.1 5,110.0%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.60.6 90.6%   
Return on assets %12.94.5 284.6%  
Return on equity %14.87.5 196.9%  
Return on capital %20.89.7 214.7%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35972,623 44.6%   
Fx outflow Rs m9,04218,916 47.8%   
Net fx Rs m23,31753,707 43.4%   
CASH FLOW
From Operations Rs m7,75918,030 43.0%  
From Investments Rs m-4,783-14,883 32.1%  
From Financial Activity Rs m-3,142-4,440 70.8%  
Net Cashflow Rs m-166-1,236 13.4%  

Share Holding

Indian Promoters % 52.0 25.5 203.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 5.4 218.5%  
FIIs % 19.0 35.3 53.8%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.2 15.3 112.4%  
Shareholders   31,796 75,885 41.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  VENUS REMEDIES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS